RNA, U6 small nuclear variant sequence with SNRPE pseudogene sequenceGenealiases: 87U6 · LH87
Q-omics provides the consensus-scored RNU6V profile across patient tissues and cancer cell-line models. RNU6V expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNU6V is differentially expressed in 11, with the highest sampling consensus in BRCA. Additionally, RNU6V RNA expression shows 11,531 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BRCA, and UVM as cancer lineages where RNU6V shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6V — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6V survival associations across molecular data types. RNU6V RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6V RNA expression–survival associations across cancer types. High RNU6V expression shows unfavorable associations in ACC, COAD, KICH and DLBC, but favorable associations in UCS and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNU6V RNA expression.
This table summarizes RNU6V tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6V. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6V shows lower tumor expression in THCA, KICH and COAD and higher tumor expression in BRCA, BLCA and STAD. The BRCA box plot shows higher RNU6V RNA expression in tumor versus normal tissue (log2 FC = +0.290, t-test p = .001).
This table shows molecular features associated with RNU6V in patient tissues and cancer cell lines. In patient samples, RNU6V shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
